Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.
Monopar has raised $135.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2025.
Monopar's investors include RA Capital Management, Janus Henderson Investors, Adage Capital Management, ADAR1 Capital Management.
Monopar is headquartered in Wilmette, United States.
Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.
Monopar is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Monopar — Funding & Investors." VCBacked, September 23, 2025, https://www.vcbacked.co/company/monopar. Accessed August 14, 2026.
VCBacked. (2025). Monopar — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/monopar
{{cite web |title=Monopar — Funding & Investors |url=https://www.vcbacked.co/company/monopar |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated